aquaculture-2018-scientifictracks-abstracts

7 / 11

Aquaculture 2018
S e p t e m b e r 2 0 - 2 1 , 2 0 1 8
L i s b o n , P o r t u g a l
Page 25
Journal of
ISSN: 1307-234X
E u r o p e a n S u mm i t o n
Aquaculture, Fisheries
and Horticulture
Streptococcus agalactiae is one of the major disease problems affecting
farmed tilapia worldwide, usually for fish that are 300-600 g in average
weight. This results in a significant economic loss for farmers. Affected
tilapia commonly present with an irregular behavior associated with anorexia,
exophthalmia, ascites and erratic swimming. It also causes septicemic
disease, affecting organs such as the brain, kidney and gut, among others.
The vaccination strategy is the most important measure for the control
of streptococcosis in fish. Nevertheless, vaccine efficacy may vary due to
the existence of different serotypes and the genetic profiles of circulating
strains. Thus monitoring, by laboratory diagnosis, is essential to understand
the prevalence of serotypes and genetic profiles existing in the country,
which directly informs the relative importance of using local bacteria and
development of autogenous vaccines. In this study, an autogenous vaccine for
hybrid tilapia ( Oreochromis niloticus x O. aurea) was developed against local
species of Streptococcus agalactiae. The entire progress, from field sampling
of the pathogenic bacteria until field application of the vaccine, is described.
This includes the isolation and identification of the bacteria, the establishment
of a seed lot system including preparation of master seed and working seed, the
fermentation process, inactivation of the antigen and vaccine preparation. Six
different emulsions were prepared in order to compare two different adjuvants
at three different antigen titers. The laboratory quality control methods and
residue of formalin are also presented. Safety and efficacy trials were carried
out for all six emulsions. Based on the efficacy results; one of the preparations
was selected as an autogenous vaccine for full-scale production. The product
was tested for onset of immunity, duration of immunity and stability. Following
the tests, it was used in a commercial farm of tilapia in Israel.
Biography
Yechiam Shapira has completed his MSc at the Hebrew
University in Jerusalem, in fish health and fish genetics. He
has published one article in Aquaculture magazine, and was
involved in two others. He worked as the Fish Health Manager
in different farms in Israel and in Mexico for the last 30 years.
His experience includes fresh water species, marine species
and ornamental fish, growing on land and in cages in the sea.
He was the president of The Israeli Society of Aquaculture and
Biotechnology for four years. In the last 4.5 years, he is a Senior
Researcher in Phibro Aqua, a division of Phibro Animal Health
Corporation.
Development of autogenous vaccine of Streptococcus
agalactiaefor hybrid tilapia from isolation to the field
Yechiam Shapira1, Ira Prsser1 , Michael Horne2 and Ra’anan Ariav1
1Phibro Animal Health Corporation, Israel
2Phyco Ltd, Scotland
Yechiam Shapira et al., Journal of Volume:12
DOI: 10.21767/1307-234X-C1-002